| | Working on an early phase oncology trial? Your trial design can make or break it. Targeted therapies are a cornerstone of precision medicine and how you design your trial is a critical factor. Download our guide to stay on the path to success. |
Sinopharm shares phase 2 data on inactivated COVID-19 vaccine CureVac banks $213M IPO to push COVID-19 vaccine, boost manufacturing Mission Bio raises $70M to scale single-cell cancer R&D platform As Urovant preps to launch Myrbetriq rival, it’s all systems go on R&D Calliditas gets controlling stake, option to buy out Genkyotex and its failed PBC drug Thermo Fisher’s $12.5B deal for Qiagen falls through, as COVID-19 test demand lights new path forward FiercePharmaAsia—Japan COVID-19 vax deals; Samsung Biologics' $2B super plant; Eisai's new U.S. HQ Chutes & Ladders—WuXi taps veteran operations head Dong to lead new vaccines unit Featured Story | By Nick Paul Taylor Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus. read more |
| |
|---|
|
| | CROs rely on data analytics to provide sponsors with continuous clinical insight of trends that could predict safety, and more importantly, efficacy for investigational products. Learn more about strategies for data analytics and evaluation from our free white paper. |
Top Stories By Amirah Al Idrus On the heels of a $640 million private round, Germany’s CureVac has netted $213 million in its Nasdaq debut. The bulk of the proceeds will bankroll its mRNA vaccine for COVID-19, with the rest going to manufacturing, platform development and other programs. The company also picked up another $118 million through a private placement to longtime investor, Dietmar Hopp. read more By Nick Paul Taylor Mission Bio has raised $70 million to scale up a single-cell multi-omics technology with applications in the development of oncology drugs. The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. read more By Amirah Al Idrus Urovant may be gearing up for its first commercial launch, but that doesn’t mean it’s taking its eye off the R&D ball. As it builds its commercial organization for its overactive bladder treatment, the company pushing the same drug through the clinic in other indications, and working on a gene therapy, too. read more By Ben Adams Calliditas is spending a little over €20 million for a controlling stake in Genkyotex in the hope it can help revive its faltering attempts in primary biliary cholangitis (PBC). read more By Conor Hale While many companies have faltered under the spread of COVID-19, others may be doing a little too well for some tastes—with Qiagen’s investors turning down Thermo Fisher’s multibillion-dollar takeover proposal, following rocketing demand for its testing products. read more By Angus Liu AstraZeneca taps Daiichi Sankyo and others to help supply its COVID-19 vaccine to Japan, as Takeda licenses Novavax's coronavirus shot for its home country. Samsung Biologics is plotting a giant $2 billion facility at its Incheon base. Eisai will relocate its U.S. headquarters. And more. read more By Kyle Blankenship WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO. read more | | Experts in our field with 20+ yrs. experience in Viral Vector & Plasmid DNA (R&D, High Quality, GMP) manufacture for pre-clinical to commercial supply. Now part of the Cognate BioServices family, Cobra has rebranded – look around our updated website. |
Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 